Angelo Mathews struck his highest Test score with an unbeaten double century on Wednesday as Sri Lanka left Zimbabwe battling to save the series opener going into the final day at Harare.
Former skipper Mathews eclipsed his previous Test best of 160 and finished 200 not out after a marathon knock spanning 468 balls, as Sri Lanka declared their first innings on 515 for nine.
Zimbabwe, playing their first Test since November 2018, ended the fourth day on 30 without loss and trailing by 127 runs after Brian Mudzinganyama was drafted in as a concussion substitute for opener Kevin Kasuza.
Debutant Kasuza, who made 63 in the first innings, suffered a delayed concussion after he took a blow to the helmet while fielding at short leg on Tuesday.
Mudzinganyama became the fourth Zimbabwean to make his Test debut in this match. He was unbeaten on 14 with Prince Masvaure 15 not out at stumps.
The 32-year-old Mathews brought up his 10th Test century, his first since December 2018, in the morning session and steadily added to his total with considerable support from Dhananjaya de Silva and Niroshan Dickwella.
He was dropped shortly after reaching his ton when wicketkeeper Regis Chakabva was unable to hold a difficult chance off left-arm spinner Ainsley Ndlovu.
De Silva and Dickwella both scored 63 but two quick wickets for Sikandar Raza, who finished with three for 62, hastened the declaration as Mathews reached 200 with a sweep to the square leg boundary.
With one day remaining, the visitors appear the only team capable of victory although the pitch looks likely to have the final say.
The two-Test tour was only announced by the Sri Lankan cricket board last week.
Zimbabwe were readmitted as an ICC member in October following a three-month suspension over political interference.
The Sri Lanka games represent their first Tests since a 1-1 series draw in Bangladesh in November 2018.
Zimbabwe last played a Test at home against the West Indies in October 2017.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.